Literature DB >> 12629003

Severe/fatal asthma.

Sally Wenzel1.   

Abstract

Severe asthma is poorly understood clinically, physiologically, and pathologically. While milder forms of asthma are generally easily treated, more severe forms often remain refractory to the best current medical care. Although some patients with severe asthma have had severe disease for most of their lives, there appears to be a second group that develops severe disease in adulthood. Additionally, it is not clear which genetic and environmental elements may be the most important in the development of severe disease. Physiologically, these patients often have airtrapping and may have loss of elastic recoil, as well. The pathology demonstrates a heterogeneity of findings, including continued eosinophilic inflammation, structural changes, distal disease, and, in at least one third of patients, a different pathology. Treatment remains problematic and likely will remain so until a better understanding of this disease develops.

Entities:  

Mesh:

Year:  2003        PMID: 12629003     DOI: 10.1378/chest.123.3_suppl.405s-a

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

1.  MicroRNA Targets for Asthma Therapy.

Authors:  Sabrina C Ramelli; William T Gerthoffer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Steroid response in refractory asthmatics.

Authors:  An-Soo Jang
Journal:  Korean J Intern Med       Date:  2012-05-31       Impact factor: 2.884

Review 3.  Management of the patient with eosinophilic asthma: a new era begins.

Authors:  Jantina C de Groot; Anneke Ten Brinke; Elisabeth H D Bel
Journal:  ERJ Open Res       Date:  2015-09-23

4.  A GATA3 Targeting Nucleic Acid Nanocapsule for In Vivo Gene Regulation in Asthma.

Authors:  Tyler D Gavitt; Alyssa K Hartmann; Shraddha S Sawant; Arlind B Mara; Steven M Szczepanek; Jessica L Rouge
Journal:  ACS Nano       Date:  2021-06-23       Impact factor: 18.027

5.  Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers.

Authors:  Neil E Alexis; John C Lay; Angela Haczku; Henry Gong; William Linn; Milan J Hazucha; Brad Harris; Ruth Tal-Singer; David B Peden
Journal:  Environ Health Perspect       Date:  2008-06       Impact factor: 9.031

Review 6.  The role of rhinosinusitis in severe asthma.

Authors:  An-Soo Jang
Journal:  Korean J Intern Med       Date:  2013-10-29       Impact factor: 2.884

Review 7.  Refractory asthma: mechanisms, targets, and therapy.

Authors:  J L Trevor; J S Deshane
Journal:  Allergy       Date:  2014-04-29       Impact factor: 13.146

8.  Nanoparticle Delivery of Anti-inflammatory LNA Oligonucleotides Prevents Airway Inflammation in a HDM Model of Asthma.

Authors:  Sabrina C Ramelli; Brian S Comer; Jared M McLendon; Lydia L Sandy; Andrew P Ferretti; Robert Barrington; Jeff Sparks; Majed Matar; Jason Fewell; William T Gerthoffer
Journal:  Mol Ther Nucleic Acids       Date:  2020-01-14       Impact factor: 8.886

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.